After nearly eight years of tangling with the Food and Drug Administration, San Luis Obipso-based FzioMed said it might receive approval to sell its products in the U.S. by year’s end.
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
